BACKGROUND AND AIMS: Evidence suggests that both the nicotinic receptor α5 subunit (CHRNA5) and Cytochrome P450 2A6 (CYP2A6) genotypes influence smoking cessation success and response to pharmacotherapy. We examine the effect of CYP2A6 genotype on smoking cessation success and response to cessation pharmacotherapy, and combine these effects with those of CHRNA5 genotypes. DESIGN:Placebo-controlled randomized smoking cessation trial. SETTING: Ambulatory care facility in Wisconsin, USA. PARTICIPANTS: Smokers (n = 709) of European ancestry were randomized to placebo, bupropion, nicotine replacement therapy or combined bupropion and nicotine replacement therapy. MEASUREMENTS: Survival analysis was used to model time to relapse using nicotine metabolism derived from CYP2A6 genotype-based estimates. Slow metabolism is defined as the lowest quartile of estimated metabolic function. FINDINGS: CYP2A6-defined nicotine metabolic function moderated the effect of smoking cessation pharmacotherapy on smoking relapse over 90 days [hazard ratio (HR) = 2.81, 95% confidence interval (CI) = 1.32-5.99, P = 0.0075], with pharmacotherapy significantly slowing relapse in fast (HR = 0.39, 95% CI = 0.28-0.55, P = 1.97 × 10(-8)), but not slow metabolizers (HR = 1.09, 95% CI = 0.55-2.17, P = 0.80). Further, only the effect of nicotine replacement, and not bupropion, varies with CYP2A6-defined metabolic function. The effect of nicotine replacement on continuous abstinence is moderated by the combined genetic risks from CYP2A6 and CHRNA5 (Wald = 7.44, d.f. = 1, P = 0.0064). CONCLUSIONS:Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. The variation in treatment responses among smokers with genes may guide future personalized smoking cessation interventions.
RCT Entities:
BACKGROUND AND AIMS: Evidence suggests that both the nicotinic receptor α5 subunit (CHRNA5) and Cytochrome P450 2A6 (CYP2A6) genotypes influence smoking cessation success and response to pharmacotherapy. We examine the effect of CYP2A6 genotype on smoking cessation success and response to cessation pharmacotherapy, and combine these effects with those of CHRNA5 genotypes. DESIGN: Placebo-controlled randomized smoking cessation trial. SETTING: Ambulatory care facility in Wisconsin, USA. PARTICIPANTS: Smokers (n = 709) of European ancestry were randomized to placebo, bupropion, nicotine replacement therapy or combined bupropion and nicotine replacement therapy. MEASUREMENTS: Survival analysis was used to model time to relapse using nicotine metabolism derived from CYP2A6 genotype-based estimates. Slow metabolism is defined as the lowest quartile of estimated metabolic function. FINDINGS:CYP2A6-defined nicotine metabolic function moderated the effect of smoking cessation pharmacotherapy on smoking relapse over 90 days [hazard ratio (HR) = 2.81, 95% confidence interval (CI) = 1.32-5.99, P = 0.0075], with pharmacotherapy significantly slowing relapse in fast (HR = 0.39, 95% CI = 0.28-0.55, P = 1.97 × 10(-8)), but not slow metabolizers (HR = 1.09, 95% CI = 0.55-2.17, P = 0.80). Further, only the effect of nicotine replacement, and not bupropion, varies with CYP2A6-defined metabolic function. The effect of nicotine replacement on continuous abstinence is moderated by the combined genetic risks from CYP2A6 and CHRNA5 (Wald = 7.44, d.f. = 1, P = 0.0064). CONCLUSIONS:Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. The variation in treatment responses among smokers with genes may guide future personalized smoking cessation interventions.
Authors: C Lerman; C Jepson; E P Wileyto; F Patterson; R Schnoll; M Mroziewicz; N Benowitz; R F Tyndale Journal: Clin Pharmacol Ther Date: 2010-03-24 Impact factor: 6.875
Authors: Thorgeir E Thorgeirsson; Daniel F Gudbjartsson; Ida Surakka; Jacqueline M Vink; Najaf Amin; Frank Geller; Patrick Sulem; Thorunn Rafnar; Tõnu Esko; Stefan Walter; Christian Gieger; Rajesh Rawal; Massimo Mangino; Inga Prokopenko; Reedik Mägi; Kaisu Keskitalo; Iris H Gudjonsdottir; Solveig Gretarsdottir; Hreinn Stefansson; John R Thompson; Yurii S Aulchenko; Mari Nelis; Katja K Aben; Martin den Heijer; Asger Dirksen; Haseem Ashraf; Nicole Soranzo; Ana M Valdes; Claire Steves; André G Uitterlinden; Albert Hofman; Anke Tönjes; Peter Kovacs; Jouke Jan Hottenga; Gonneke Willemsen; Nicole Vogelzangs; Angela Döring; Norbert Dahmen; Barbara Nitz; Michele L Pergadia; Berta Saez; Veronica De Diego; Victoria Lezcano; Maria D Garcia-Prats; Samuli Ripatti; Markus Perola; Johannes Kettunen; Anna-Liisa Hartikainen; Anneli Pouta; Jaana Laitinen; Matti Isohanni; Shen Huei-Yi; Maxine Allen; Maria Krestyaninova; Alistair S Hall; Gregory T Jones; Andre M van Rij; Thomas Mueller; Benjamin Dieplinger; Meinhard Haltmayer; Steinn Jonsson; Stefan E Matthiasson; Hogni Oskarsson; Thorarinn Tyrfingsson; Lambertus A Kiemeney; Jose I Mayordomo; Jes S Lindholt; Jesper Holst Pedersen; Wilbur A Franklin; Holly Wolf; Grant W Montgomery; Andrew C Heath; Nicholas G Martin; Pamela A F Madden; Ina Giegling; Dan Rujescu; Marjo-Riitta Järvelin; Veikko Salomaa; Michael Stumvoll; Tim D Spector; H-Erich Wichmann; Andres Metspalu; Nilesh J Samani; Brenda W Penninx; Ben A Oostra; Dorret I Boomsma; Henning Tiemeier; Cornelia M van Duijn; Jaakko Kaprio; Jeffrey R Gulcher; Mark I McCarthy; Leena Peltonen; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2010-04-25 Impact factor: 38.330
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker Journal: Arch Gen Psychiatry Date: 2009-11
Authors: George R Uhl; Qing-Rong Liu; Tomas Drgon; Catherine Johnson; Donna Walther; Jed E Rose; Sean P David; Ray Niaura; Caryn Lerman Journal: Arch Gen Psychiatry Date: 2008-06
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Jason Z Liu; Federica Tozzi; Dawn M Waterworth; Sreekumar G Pillai; Pierandrea Muglia; Lefkos Middleton; Wade Berrettini; Christopher W Knouff; Xin Yuan; Gérard Waeber; Peter Vollenweider; Martin Preisig; Nicholas J Wareham; Jing Hua Zhao; Ruth J F Loos; Inês Barroso; Kay-Tee Khaw; Scott Grundy; Philip Barter; Robert Mahley; Antero Kesaniemi; Ruth McPherson; John B Vincent; John Strauss; James L Kennedy; Anne Farmer; Peter McGuffin; Richard Day; Keith Matthews; Per Bakke; Amund Gulsvik; Susanne Lucae; Marcus Ising; Tanja Brueckl; Sonja Horstmann; H-Erich Wichmann; Rajesh Rawal; Norbert Dahmen; Claudia Lamina; Ozren Polasek; Lina Zgaga; Jennifer Huffman; Susan Campbell; Jaspal Kooner; John C Chambers; Mary Susan Burnett; Joseph M Devaney; Augusto D Pichard; Kenneth M Kent; Lowell Satler; Joseph M Lindsay; Ron Waksman; Stephen Epstein; James F Wilson; Sarah H Wild; Harry Campbell; Veronique Vitart; Muredach P Reilly; Mingyao Li; Liming Qu; Robert Wilensky; William Matthai; Hakon H Hakonarson; Daniel J Rader; Andre Franke; Michael Wittig; Arne Schäfer; Manuela Uda; Antonio Terracciano; Xiangjun Xiao; Fabio Busonero; Paul Scheet; David Schlessinger; David St Clair; Dan Rujescu; Gonçalo R Abecasis; Hans Jörgen Grabe; Alexander Teumer; Henry Völzke; Astrid Petersmann; Ulrich John; Igor Rudan; Caroline Hayward; Alan F Wright; Ivana Kolcic; Benjamin J Wright; John R Thompson; Anthony J Balmforth; Alistair S Hall; Nilesh J Samani; Carl A Anderson; Tariq Ahmad; Christopher G Mathew; Miles Parkes; Jack Satsangi; Mark Caulfield; Patricia B Munroe; Martin Farrall; Anna Dominiczak; Jane Worthington; Wendy Thomson; Steve Eyre; Anne Barton; Vincent Mooser; Clyde Francks; Jonathan Marchini Journal: Nat Genet Date: 2010-04-25 Impact factor: 38.330
Authors: Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen Journal: Pharmacogenomics Date: 2018-06-19 Impact factor: 2.533
Authors: Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan Journal: Nicotine Tob Res Date: 2015-05-19 Impact factor: 4.244
Authors: Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2018-01 Impact factor: 2.089